Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Legend Biotech Q3 Adj. EPS $(0.05) Beats $(0.10) Estimate, Sales $272.330M Miss $272.499M Estimate

Author: Benzinga Newsdesk | November 12, 2025 07:00am
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 54.55 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $272.330 million which missed the analyst consensus estimate of $272.499 million by 0.06 percent. This is a 69.99 percent increase over sales of $160.205 million the same period last year.

Posted In: LEGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist